# VSIG4

## Overview
VSIG4, or V-set and immunoglobulin domain containing 4, is a gene that encodes a protein belonging to the immunoglobulin superfamily, characterized by its immunoglobulin-like domains. The VSIG4 protein functions primarily as a complement receptor and a negative regulator of T cell activation, playing a pivotal role in immune regulation. It is predominantly expressed on macrophages in various tissues, including the liver, spleen, and thymic medulla, where it contributes to immune homeostasis by inhibiting T cell proliferation and cytokine production. Additionally, VSIG4 is involved in the immune response against intracellular bacterial infections by promoting autophagy, thereby enhancing pathogen clearance. The protein's interactions with complement components and other cell surface molecules underscore its significance in modulating immune responses, making it a potential target for therapeutic interventions in cancer and inflammatory diseases (Vogt2006VSIG4; Kim2016Extracellular).

## Structure
The VSIG4 protein, encoded by the VSIG4 gene, is a member of the immunoglobulin superfamily and features immunoglobulin-like domains that are crucial for its function in immune regulation (Ebstein2023VSIG4). The primary structure of VSIG4 includes a V-set immunoglobulin domain, which is involved in its role as a complement receptor and a negative regulator of T cell activation (Wen2017Structural). The protein's secondary structure likely includes beta sheets and alpha helices, typical of immunoglobulin domains, although specific details are not provided in the context.

VSIG4 is known to interact with complement components C3b and iC3b, and its structure includes binding sites for these components, as well as for heparan sulfates, which can inhibit complement binding (Ebstein2023VSIG4). The protein's tertiary structure is characterized by positively charged patches that facilitate these interactions (Ebstein2023VSIG4). The quaternary structure involves the formation of complexes with nanobodies, such as Nb119, which target the complement receptor domain of VSIG4 (Wen2017Structural).

Post-translational modifications, such as glycosylation, may influence the stability and function of VSIG4, although specific modifications are not detailed in the context. The protein may exist in different isoforms due to alternative splicing, which can affect its functional properties (Ebstein2023VSIG4).

## Function
VSIG4 (V-set and immunoglobulin domain containing 4) is a protein that functions as a negative regulator of T cell activation, primarily expressed on macrophages in various tissues such as the liver, spleen, and thymic medulla (Vogt2006VSIG4). It plays a crucial role in maintaining immune homeostasis by inhibiting T cell proliferation and IL-2 production, thereby preventing excessive immune responses in healthy tissues (Vogt2006VSIG4). VSIG4 is also involved in the regulation of immune responses through its role as a complement receptor, known as CRIg, which links innate immunity with T cell activation regulation (Vogt2006VSIG4).

In addition to its role in T cell regulation, VSIG4 is implicated in the immune defense against intracellular bacterial infections. It promotes autophagy by inducing the formation of autophagosomes, which target intracellular pathogens like Listeria monocytogenes for degradation (Kim2016Extracellular). This autophagic process is crucial for controlling bacterial growth within macrophages and enhancing pathogen clearance (Kim2016Extracellular). Through these mechanisms, VSIG4 contributes to both immune tolerance and defense, maintaining a balance between preventing autoimmunity and responding to infections.

## Clinical Significance
Alterations in the expression of the VSIG4 gene have been implicated in various diseases and conditions. In hepatocellular carcinoma (HCC), particularly in patients with hepatitis B virus (HBV) infection, low VSIG4 expression is associated with poor prognosis. Patients with reduced VSIG4 levels exhibit shorter overall and disease-free survival, suggesting that VSIG4 may serve as a prognostic marker for HBV-related HCC (Zhu2018Low). 

In the context of inflammatory disorders, VSIG4 plays a role in regulating macrophage activation and inflammation. Deficiency in VSIG4 leads to increased proinflammatory cytokine production and severe liver necrosis in viral fulminant hepatitis models, indicating its protective role against excessive inflammation (Li2017VSIG4). VSIG4 also mediates transcriptional inhibition of the NLRP3 inflammasome and IL-1β in macrophages, with its deficiency resulting in increased severity of conditions like experimental autoimmune encephalomyelitis (EAE) and colitis (Huang2019VSIG4).

In cancer, VSIG4 is involved in immune evasion, with higher expression linked to increased tumor growth. Its deficiency has been shown to suppress tumor growth in experimental models, highlighting its potential as a target for cancer therapy (Hall2020Immune).

## Interactions
VSIG4, also known as V-set and immunoglobulin domain containing 4, is a protein that participates in several key interactions within the immune system. It acts as a complement receptor with high affinity for the complement components C3b and iC3b, facilitating the clearance of pathogens by macrophages and inhibiting the alternative complement pathway (Zhou2022VSet; Ebstein2023VSIG4). VSIG4 also interacts with heparan sulfates (HS) on the cell surface, which are necessary for its binding. This interaction inhibits VSIG4's binding to complement fragments, suggesting a regulatory role in immune responses (Ebstein2023VSIG4).

VSIG4 forms a surface inhibitory signaling complex with the transmembrane protein MS4A6D, which suppresses the expression of NLRP3 and IL-1β in macrophages. This interaction triggers phosphorylation events that activate the JAK2-STAT3-A20 cascade, reducing nuclear factor κB activity and subsequently repressing NLRP3 and IL-1β transcription (Huang2019VSIG4). As a coinhibitory ligand, VSIG4 suppresses T-cell proliferation and cytokine production, inducing T-cell anergy and promoting differentiation towards regulatory T cells (Treg) (Zhou2022VSet). These interactions highlight VSIG4's role in modulating immune responses and its potential as a target for cancer immunotherapy.


## References


[1. (Ebstein2023VSIG4) Sarah Y Ebstein, Ashique Rafique, Yi Zhou, Amanda Krasco, Welby Montalvo-Ortiz, Lola Yu, Luisaidy Custodio, Rene C Adam, Nicolin Bloch, Ken Lee, Funmilola Adewale, Dominic Vergata, Antonio Luz, Sebastien Coquery, Benjamin Daniel, Erica Ullman, Matthew C Franklin, Aynur Hermann, Tammy Huang, William Olson, Samuel Davis, Andrew J Murphy, Matthew A Sleeman, Joyce Wei, and Dimitris Skokos. Vsig4 interaction with heparan sulfates inhibits vsig4–complement binding. Glycobiology, 33(7):591–604, June 2023. URL: http://dx.doi.org/10.1093/glycob/cwad050, doi:10.1093/glycob/cwad050. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1093/glycob/cwad050)

[2. (Zhou2022VSet) Xia Zhou, Sohail Khan, Dabing Huang, and Lu Li. V-set and immunoglobulin domain containing (vsig) proteins as emerging immune checkpoint targets for cancer immunotherapy. Frontiers in Immunology, September 2022. URL: http://dx.doi.org/10.3389/fimmu.2022.938470, doi:10.3389/fimmu.2022.938470. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2022.938470)

[3. (Zhu2018Low) Sicong Zhu, Wenliang Tan, Wenxin Li, Rui Zhou, Xiaolin Wu, Xianqing Chen, Wenda Li, Changzhen Shang, and Yajin Chen. Low expression of vsig4 is associated with poor prognosis in hepatocellular carcinoma patients with hepatitis b infection. Cancer Management and Research, Volume 10:3697–3705, September 2018. URL: http://dx.doi.org/10.2147/CMAR.S165822, doi:10.2147/cmar.s165822. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.2147/CMAR.S165822)

[4. (Huang2019VSIG4) Xiaoyong Huang, Zeqing Feng, Yuanzhong Jiang, Jialin Li, Qun Xiang, Sheng Guo, Chengying Yang, Lei Fei, Guoning Guo, Lixin Zheng, Yuzhang Wu, and Yongwen Chen. Vsig4 mediates transcriptional inhibition of nlrp3 and il-1 β in macrophages. Science Advances, January 2019. URL: http://dx.doi.org/10.1126/sciadv.aau7426, doi:10.1126/sciadv.aau7426. This article has 77 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/sciadv.aau7426)

[5. (Vogt2006VSIG4) L. Vogt, N. Schmitz, M. O. Kurrer, M. Bauer, H. I. Hinton, S. Behnke, D. Gatto, P. Sebbel, R. R. Beerli, I. Sonderegger, M. Kopf, P. Saudan, and M. F. Bachmann. Vsig4, a b7 family-related protein, is a negative regulator of t cell activation. Journal of Clinical Investigation, 116(10):2817–2826, October 2006. URL: http://dx.doi.org/10.1172/jci25673, doi:10.1172/jci25673. This article has 209 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci25673)

[6. (Hall2020Immune) Brandon M. Hall, Anatoli S. Gleiberman, Evguenia Strom, Peter A. Krasnov, David Frescas, Slavoljub Vujcic, Olga V. Leontieva, Marina P. Antoch, Valeria Kogan, Igor E. Koman, Yi Zhu, Tamara Tchkonia, James L. Kirkland, Olga B. Chernova, and Andrei V. Gudkov. Immune checkpoint protein vsig4 as a biomarker of aging in murine adipose tissue. Aging Cell, August 2020. URL: http://dx.doi.org/10.1111/acel.13219, doi:10.1111/acel.13219. This article has 20 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/acel.13219)

[7. (Li2017VSIG4) Jialin Li, Bo Diao, Sheng Guo, Xiaoyong Huang, Chengying Yang, Zeqing Feng, Weiming Yan, Qin Ning, Lixin Zheng, Yongwen Chen, and Yuzhang Wu. Vsig4 inhibits proinflammatory macrophage activation by reprogramming mitochondrial pyruvate metabolism. Nature Communications, November 2017. URL: http://dx.doi.org/10.1038/s41467-017-01327-4, doi:10.1038/s41467-017-01327-4. This article has 116 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-017-01327-4)

[8. (Wen2017Structural) Yurong Wen, Zhenlin Ouyang, Steve Schoonooghe, Siyu Luo, Patrick De Baetselier, Wuyuan Lu, Serge Muyldermans, Geert Raes, and Fang Zheng. Structural evaluation of a nanobody targeting complement receptor vsig4 and its cross reactivity. Immunobiology, 222(6):807–813, June 2017. URL: http://dx.doi.org/10.1016/j.imbio.2016.11.008, doi:10.1016/j.imbio.2016.11.008. This article has 23 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.imbio.2016.11.008)

[9. (Kim2016Extracellular) Kwang H. Kim, Beom K. Choi, Young H. Kim, Chungyong Han, Ho S. Oh, Don G. Lee, and Byoung S. Kwon. Extracellular stimulation of vsig4/complement receptor ig suppresses intracellular bacterial infection by inducing autophagy. Autophagy, 12(9):1647–1659, August 2016. URL: http://dx.doi.org/10.1080/15548627.2016.1196314, doi:10.1080/15548627.2016.1196314. This article has 29 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1080/15548627.2016.1196314)